Back HBV Disease Progression

HBV Disease Progression

FDA Approves Nivolumab Immunotherapy for Liver Cancer

In September, the U.S. Food and Drug Administration granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).

alt

Read more:

FDA Approves Nivolumab Immunotherapy for Liver Cancer

In September, the U.S. Food and Drug Administrationgranted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).

alt

Read more:

EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer

The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival

Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.

alt

Read more:

AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?

The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among chronic hepatitis B patients treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD Liver Meeting in Boston. However, liver cancer remains a major indication for liver transplants and has a negative effect on survival of people with hepatitis B.

alt

Read more: